CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Loading researcher profile…

Anonymous aggregate analytics use the connection IP transiently only to derive country; the IP is not stored in analytics data. DNT and GPC are honored, with 90-day retention. IP Geolocation by DB-IP.

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Researchers/Profile

Researcher profile

Taylan Gurgenci

OPENALEX: A5043171227↗ORCID: 0000-0001-9695-9109↗

Affiliations

Organizations

Mater Adult Hospitalauthorship · AU Mater Health Servicesauthorship · AU Mater Misericordiae Hospitalauthorship · AU Mater Researchauthorship · AU The University of Queenslandauthorship · AU

Public evidence

4 connected articles

Medicinal cannabis for symptom control in advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of 1:1 tetrahydrocannabinol and cannabidiol.2025 · Europe PMC Medicinal Cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer-a study protocol for a randomised controlled trial.2024 · Europe PMC Exploring potential anti-inflammatory effects of medicinal cannabis.2023 · PubMed Central Open Access 'What price do you put on your health?': Medical cannabis, financial toxicity and patient perspectives on medication access in advanced cancer.2022 · PubMed Central Open Access

Matched by exact identifiers only. Profile data: Corpus/OpenAlex.

Taylan Gurgenci - Medical Cannabis Research Engine